ArticleBMC infectious diseases2026
Bacterial uropathogens, associated factors, and ESBL-producing gram-negative isolates in diabetic patients at Debre Markos comprehensive specialized hospital, Ethiopia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study assessed the prevalence of bacterial uropathogens, antibiotic resistance, associated factors, and extended-spectrum β-lactamases ( ESBL)-producing Enterobacteriaceae uropathogens in diabetes mellitus (DM) patients at Debre Markos Comprehensive Specialized Hospital, Ethiopia. A cross-sectional study was conducted from April to July 2023 among 189 DM patients. Urine samples were processed using standard urine culture techniques. Bacterial identification was performed based on colony morphology on culture media, Gram staining, microscopic examination, and biochemical tests. Antimicrobial susceptibility testing was performed using the Kirby–Bauer disc diffusion method, and ESBL production was confirmed by the combination disc method according to CLSI guidelines for Enterobacteriaceae. Significant bacteriuria was found in 17.5% (33/189), higher in females (27.6%) than males (8.8%). Identified risk factors included female sex, age 25–34, prior UTI, and recent hospitalization. Escherichia coli (45.5%) was the predominant isolate. Multidrug resistance (MDR) was observed in 42.4% of isolates, and 57.9% of Gram-negative bacteria were ESBL producers.These findings highlight the clinical significance of high MDR and ESBL prevalence, emphasizing challenges in empiric therapy and the importance of routine susceptibility testing among diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.